权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Modulating the PD-1/PD-L1 checkpoint to promote antitumor activity of HER2 CAR T cells in patients with sarcoma

调节PD-1/PD-L1检查点促进肉瘤患者HER2 CAR T细胞的抗肿瘤活性

基本信息

批准号：
10562836
负责人：
Meenakshi G Hegde
金额：
$ 66.78万
依托单位：
BAYLOR COLLEGE OF MEDICINE
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-03-07 至 2028-02-29
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10562836
关键词：
Address Adoptive Transfer Adult Antigen Targeting Antigens Antitumor Response Autologous Biology CAR T cell therapy CD19 gene CD8B1 gene Cell Line Cell Separation Cell Therapy Cells Chemotherapy-Oncologic Procedure Child Clinic Clinical Clinical Research Clinical Trials Combination immunotherapy Cyclophosphamide Data Development Disease Dose Down-Regulation ERBB2 gene Engineering Event Functional disorder Future Goals Hematologic Neoplasms Immune Immune checkpoint inhibitor Immune signaling Immunologic Markers Immunotherapy In complete remission Infusion procedures Intervention Investigational Drugs Investigational New Drug Application Kinetics Knowledge Literature Malignant Neoplasms Observational Study Outcome PD-1 blockade PD-1/PD-L1 Patient Selection Patients Pharmaceutical Preparations Phase Phase I Clinical Trials Predisposition Property Public Health ROR1 gene Recurrence Recurrent disease Refractory Relapse Reporting Research Research Personnel Rhabdomyosarcoma Safety Serum Signal Transduction Solid Neoplasm T cell response T-Cell Receptor T-Lymphocyte Testing Therapeutic Toxic effect Transgenes Treatment outcome Tumor Antigens Tumor Escape Tumor Promotion Tumor Tissue Up-Regulation anti-PD1 antibodies antitumor effect biomarker identification cell mediated immune response checkpoint inhibition chemotherapy childhood sarcoma chimeric antigen receptor T cells clinical efficacy clinical predictors cohort design fludarabine immune cell infiltrate immune checkpoint immune checkpoint blockade improved innovation novel strategies peripheral blood phase 1 study phase I trial preclinical study predictive marker programmed cell death ligand 1 programmed cell death protein 1 prospective rational design receptor research clinical testing response sarcoma success treatment response tumor tumor microenvironment years of life lost young adult

项目摘要

PROJECT SUMMARY/ABSTRACT Immunotherapy has shown limited efficacy against pediatric sarcoma. In our recently completed phase I study, infusion of HER2-targeted chimeric antigen receptor T cells (CAR-T) was safe and showed encouraging indicators of antitumor activity, including three durable complete responses. The key observations from this study are: (1) lymphodepletion promotes CAR-T expansion but only marginally improves persistence, (2) adoptively transferred CAR-T are susceptible to immune inhibition, and (3) antigen downregulation/loss is associated with disease relapse. While the literature is lacking on immune inhibitory mechanisms and tumor adaptations in sarcoma, our findings are in line with observations made by others in early clinical and pre-clinical studies of cellular therapy for solid tumors. Our long-term goal is to develop new approaches that capitalize on expected tumor defenses which may be key to unleashing the potential of CAR-T against sarcomas and other solid tumors. Therapeutic approaches that integrate strategies to address these compensatory mechanisms up front may mitigate downstream tumor escape and relapse. The objective of this project is to conduct prospective clinical testing of HER2 CAR-T in combination with PD-1/PD-L1 checkpoint disruption strategies in a disease-specific cohort. The central hypothesis is that the combination immunotherapy will promote immune infiltration, remodel the tumor microenvironment, alleviate CAR-T dysfunction, and thereby improve antitumor responses. Our specific aims will test the following hypotheses: (Aim 1) The combination of anti-PD-1 antibody and HER2 CAR- T administered after lymphodepletion is safe in patients with sarcoma, will improve CAR-T kinetics, and will elicit antitumor responses; (Aim 2) Cellular and serum-based studies in treated patients will help identify biomarkers of toxicity and response; and (Aim 3) Engineering CAR-T to positively transform the PD-1/PD-L1 interaction in the tumor microenvironment will potentiate antitumor effects of the cellular product while incorporating design attributes to enhance its safety . We will evaluate Aims 1 and 2 through implementation of a phase I study of autologous HER2 CAR-T and anti-PD-1 antibody after cyclophosphamide and fludarabine lymphodepletion in patients with sarcoma (HEROS 3.0 clinical trial). In Aim 3, we will develop an investigational new drug (IND) for HER2 CAR-T co-expressing a PD-1 checkpoint reversal receptor (CPR). At the conclusion of the project, we will understand if CAR-T can be safely administered with immune checkpoint inhibition to improve treatment outcomes for children and young adults with sarcoma. The significance of these contributions are: (1) establishing the clinical utility of combination immunotherapy for sarcoma, (2) potentially identifying “modifiable” patient- and treatment-related factors to guide future improvements to CAR-T therapy, and (3) enabling clinical testing of an innovative CAR-T platform. This knowledge is critical to advancing the field, as recurrent or refractory sarcomas remain largely incurable.

项目总结/文摘